

REMARKS

The claims have been amended to clarify that the Factor VIII included in the compositions is "native" Factor VIII. This term has been defined in earlier applications in this family to clarify that the Factor VIII is not in its "activated" form, which results when the native Factor VIII is treated with an activating enzyme, such as thrombin. In addition, the limitation in claim 4 has been imported into claim 1 in substitution for the limitation for inclusion of histidine in the composition. Claim 6 has been written in a form dependent on claim 1. Other modifications to the language conform the claims to those pending in parent applications. No new matter has been added and entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 559662000103.

Respectfully submitted,

Dated: August 25, 2004

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125